Danaher (DHR) Q4 FY25 earnings call

Danaher concluded FY25 with a strong fourth quarter, exceeding expectations across key financial metrics, particularly in bioprocessing and diagnostics. The company anticipates continued gradual end-market improvements into 2026, with bioprocessing expected to maintain high single-digit growth and diagnostics showing higher growth as China policy headwinds moderate. Management highlighted a constructive M&A environment and a strong balance sheet for future value creation.